Product Overview

COVID-19 Spike (4000 nt) mRNA (modified) encodes the full-length Spike (S) protein of SARS-CoV-2 and incorporates N1-methylpseudouridine (N1-Me-pUTP) modification to enhance mRNA performance in mammalian expression systems.

The Spike protein is a major antigenic component of SARS-CoV-2 and plays an important role in coronavirus infection research, vaccine antigen development, and immune response evaluation. Modified Spike mRNA containing N1-Me-pUTP is widely used in mRNA research due to its improved translation performance and reduced innate immune activation compared with conventional unmodified mRNA.

This product is synthesized through in vitro co-transcriptional capping technology using modified nucleotides and purified through precipitation and desalting processes. With a theoretical length of approximately 4,179 nt, COVID-19 Spike (4000 nt) mRNA (modified) provides sustained protein expression capability in eukaryotic mammalian cells and is suitable for advanced mRNA-based research applications.

Amino Acid Sequence of Encoded Protein：

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT*

Key Features

N1-Me-pUTP Modified mRNA Technology

Incorporates N1-methylpseudouridine (N1-Me-pUTP), a widely adopted nucleotide modification strategy for improving mRNA translation performance and reducing unwanted immune recognition.

Enhanced Protein Expression Performance

Validated through cellular expression assays, modified Spike mRNA demonstrates higher protein expression levels compared with unmodified mRNA products.

Improved mRNA Stability

• Maintains stability for 1 month at 2–8℃.

• Supports more than 10 freeze-thaw cycles without significant performance loss.

Research-Grade Quality and Customization Support

• Produced using optimized in vitro transcription and purification processes.

• Short lead time and flexible customization options available.

Applications

COVID-19 Spike (4000 nt) mRNA (modified) is suitable for:

• Modified mRNA technology research

• SARS-CoV-2 Spike antigen expression studies

• Vaccine research and antigen design

• Immune response analysis

• Cell-based protein expression assays

• Animal model evaluation

• mRNA delivery system development

• Translational mRNA platform research

Performance Data

Cellular Expression Validation

N1-Me-pUTP modified COVID-19 Spike mRNA demonstrates enhanced protein expression performance in mammalian cell expression assays compared with unmodified mRNA.

Stability at 2–8℃

The product maintains stability during refrigerated storage for up to 1 month, supporting experimental preparation and short-term storage.

Freeze-Thaw Stability

The modified mRNA maintains functional performance after more than 10 freeze-thaw cycles.

Long-Term Storage Stability

The product remains stable during long-term storage at -80℃, ensuring consistent performance for extended research projects.

FAQ

Q1: What is the difference between COVID-19 Spike (4000 nt) mRNA and modified mRNA?

A: The modified product incorporates N1-methylpseudouridine (N1-Me-pUTP), which can improve translation efficiency and reduce innate immune stimulation compared with conventional unmodified mRNA.

Q2: What modification is used in this product?

A: The product uses N1-methylpseudouridine (N1-Me-pUTP) modification during mRNA synthesis.

Q3: What are the recommended storage conditions?

A: Recommended storage condition is -85℃ to -65℃.

Q4: How should the product be transported?

A: Transportation is supported under -45℃ to 25℃ conditions with appropriate cold-chain packaging.

Q5: Can sequence or formulation be customized?

A: Yes. Customized mRNA sequences, nucleotide modifications, and production specifications are available based on project requirements.

Related Products